ASRT Overview

Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Wall Street analysts forecast ASRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASRT is40.00 USD with a low forecast of 35.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Assertio Holdings Inc revenue for the last quarter amounts to 9.93M USD, decreased -62.50

Assertio Holdings Inc. EPS for the last quarter amounts to -2.93 USD, increased 38.21

Assertio Holdings Inc (ASRT) has 53 emplpoyees as of May 20 2026.

Today ASRT has the market capitalization of 150.70M USD.